NCT00709917已完成不适用
Observational Study Investigating the Efficacy of Switching From Metformin Monotherapy to a Dual Therapy of Metformin and Repaglinide on Glycaemic Control in Type 2 Diabetes
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2,171
- 主要终点
- Safety (number of hypoglycaemic incidents)
研究概览
简要总结
This study is conducted in Europe.
The aim of this observational study is to investigate the switch from metformin alone to metformin combined with repaglinide in type 2 diabetic patients not achieving adequate glycaemic control on maximal dose of metformin given alone and to analyse different epidemiological parameters.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 diabetic patients with inadequate glycaemic control when received metformin alone on maximal dose
- •Signed informed consent
- •Treatment in accordance with the summary of product characterisation
排除标准
- •Any contraindication to metformin or repaglinide
研究组 & 干预措施
A
干预措施: repaglinide (Drug)
结局指标
主要结局
Safety (number of hypoglycaemic incidents)
时间窗: After 10-20 weeks
HbA1C
时间窗: After 10-20 weeks
次要结局
- safety(After 10-20 weeks)
- posology(After 10-20 weeks)
- lifestyle(After 10-20 weeks)
- FBG(After 10-20 weeks)
研究者
相似试验
已完成
不适用
Observational Study on Levemir® in Obese Diabetic PatientsDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2NCT00849342Novo Nordisk A/S580
已完成
不适用
Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00704223Novo Nordisk A/S619
已完成
不适用
Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in MacedoniaDiabetesDiabetes Mellitus, Type 2NCT00842894Novo Nordisk A/S3,421
已完成
不适用
An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin®Growth Hormone DisorderAdult Growth Hormone DeficiencyNCT00934063Novo Nordisk A/S121
已完成
不适用
Switch From Metformin Monotherapy to a Bitherapy With Metformin and RepaglinideDiabetesDiabetes Mellitus, Type 2NCT00745433Novo Nordisk A/S906